New spinal fluid biomarker distinguishes Parkinson's and Lewy body dementia from Alzheimer's disease Immunoassays measuring DOPA decarboxylase in cerebrospinal fluid achieve high diagnostic accuracy.

https://www.drugdiscoverynews.com/new-spinal-fluid-biomarker-distinguishes-parkinson-s-and-lewy-body-dementia-from-alzheimer-s-disease-17091 Diagnosing dementia with Lewy bodies (DLB) has long been one of neurology's more stubborn problems. The condition shares significant symptom overlap with Alzheimer's disease (AD) and other dementias, and misdiagnosis is common — with real consequences, since treatments effective for one condition can be harmful in another. A new study published in Nature Medicine may change that.